You are here

Innovations in rTMS Treatment


Warning message

This webinar is restricted to registered participants or on-demand registrants. Click the following link to register: Register Here

Presenting: Innovations in rTMS Treatment

You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
Innovations in rTMS Treatment

Learning objectives:

  1. Learners will be able to identify conventional rTMS strategies to treat medication resistance depression.
  2. Learners will be able to identify novel brain mechanisms that may help to identify treatment resistant depression.
  3. Learners will be able to identify novel rTMS treatment strategies to treat depression when conventional approaches do not work.


Date of Release: June 7, 2019

Date of Completion: June 6, 2021

Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

Speakers: Jeff Daskalakis, MD, PhD

Jeff Daskalakis is a Professor of Psychiatry at University of Toronto. He is presently the Temerty Chair in Therapeutic Brain Intervention and chief of the General Adult Psychiatry and Health Systems Division at CAMH. The Temerty Centre uses magnetic brain stimulation to study the role of cortical inhibition and plasticity as potential pathophysiological mechanisms in schizophrenia, depression and obsessive compulsive disorder. Dr. Daskalakis also conducts treatment studies using repetitive transcranial magnetic brain stimulation (rTMS) and magnetic seizure therapy (MST) for refractory symptoms in these disorders. He holds or has held NARSAD, CIHR, Brain Canada and NIMH operating awards and grants. He has also been awarded the Samarthji Lal Award in Mental Health Research from the Graham Boeckh Foundation. He is also a member of the Brain and Behavior Research Foundation Scientific Council. Finally, he has over 320 peer-reviewed publications and is an editorial board member for Biological Psychiatry and an Associate Editor for Clinical Neurophysiology.

Vertical Tabs

Vertical Tabs

Acknowledgement of Commercial Support

No financial or in-kind commercial support was received for this educational activity.

Satisfactory completion
Learners must complete an evaluation to receive a certificate of completion. You must participate in the entire webinar; partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.




In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Method of Physician Participation
Learners will listen to each audio self-directed module while following along with the visual slides. Upon completion, each learner will answer evaluation questions to receive their CE certificate.

Bibliographic Sources
See slides for bibliographic sources for further study.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­6.2, 6.5)


All individuals in a position to control the content of CE are listed below.


Fist Name

Last Name

Commercial Interest:Relationship



American Psychiatric Association Publishing:Other

Z. Jeff


Brainsway Inc:Research Grant Site Principal Investigator,Magventure:Research Grant Site Principal Investigator






Greenbrook TMS:Stock Shareholder








Questions? Email